GlassScriptPhysician profile
Michael H Salinger
NPI 1255416228
$215,903.91
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $91K · 2021: $42K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $138,789.01 | 2019-2021 | |
| Boston Scientific Corporation | $73,993.45 | 2019-2021 | |
| Abbott Laboratories | $1,655.57 | 2019 | |
| Artivion, INC. | $466.35 | 2020 | |
| Siemens Medical Solutions USA, INC. | $240.88 | 2019-2020 | |
| Abiomed | $161.10 | 2019-2021 | |
| Akcea Therapeutics, INC. | $139.76 | 2019 | |
| W. L. Gore & Associates, INC. | $99.95 | 2019 | |
| Penumbra, INC. | $30.00 | 2019 | |
| Medtronic, INC. | $24.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Salinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.